News
AKTX
1.300
-0.41%
-0.005
Weekly Report: what happened at AKTX last week (0317-0321)?
Weekly Report · 4d ago
Akari Therapeutics appoints Abizer Gaslightwala as CEO
Seeking Alpha · 03/20 12:44
Akari Therapeutics Appoints Abizer Gaslightwala As President And CEO
Benzinga · 03/20 12:37
AKARI THERAPEUTICS PLC - CURRENT PRESIDENT AND CEO SAMIR PATEL TO REMAIN AS BOARD MEMBER
Reuters · 03/20 12:35
AKARI THERAPEUTICS APPOINTS BIOTECHNOLOGY INDUSTRY LEADER, ABIZER GASLIGHTWALA, AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
Reuters · 03/20 12:35
Weekly Report: what happened at AKTX last week (0310-0314)?
Weekly Report · 03/17 09:59
Weekly Report: what happened at AKTX last week (0303-0307)?
Weekly Report · 03/10 10:00
Akari Therapeutics announces $7.6 million private placement
Seeking Alpha · 03/03 14:27
Akari Therapeutics announces $7.6M private placement offering
TipRanks · 03/03 14:16
Akari Therapeutics Announces $7.6M Private Placement Offering Led By Existing Shareholders And Insiders Of 6,637,626 Unregistered American Depository Shares At A Price Of $0.87 Per ADS
Benzinga · 03/03 14:10
AKARI THERAPEUTICS ANNOUNCES $7.6 MILLION PRIVATE PLACEMENT OFFERING LED BY EXISTING SHAREHOLDERS AND INSIDERS PRICED AT THE MARKET UNDER NASDAQ RULES
Reuters · 03/03 14:00
Weekly Report: what happened at AKTX last week (0224-0228)?
Weekly Report · 03/03 10:00
Weekly Report: what happened at AKTX last week (0217-0221)?
Weekly Report · 02/24 10:00
Weekly Report: what happened at AKTX last week (0210-0214)?
Weekly Report · 02/17 09:59
Weekly Report: what happened at AKTX last week (0203-0207)?
Weekly Report · 02/10 09:56
Akari Therapeutics joins Webull Corporate Connect Service
TipRanks · 02/03 13:05
Weekly Report: what happened at AKTX last week (0127-0131)?
Weekly Report · 02/03 09:58
Weekly Report: what happened at AKTX last week (0120-0124)?
Weekly Report · 01/27 09:59
Weekly Report: what happened at AKTX last week (0113-0117)?
Weekly Report · 01/20 09:56
Akari Therapeutics Showcases Advancements in Cancer Treatment
TipRanks · 01/13 13:41
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.